Protein-tyrosine kinase inhibitor

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

1 month ago talkbio0Tagged ARROS-1 trial, Frequency of Responses, Metastatic malignant neoplasm to brain, Neoplasms, Non-Small Cell Lung Carcinoma, Nuvalent, Protein-tyrosine kinase inhibitor, ROS1-positive Lung Cancer, Submission, United States Food and Drug Administration, zidesamtinib

Nuvalent; ROS1-positive lung cancer; zidesamtinib; FDA submission; ARROS-1 trial; NSCLC; tyrosine kinase inhibitor; objective response rate; brain metastases; oncology

Nuvation Bio Scores First FDA Approval for Oral Lung Cancer Drug Ibtrozi

1 month ago talkbio0Tagged Approved, Bio, IBTROZI, Malignant neoplasm of lung, Nuvation, Oral treatment, Protein-tyrosine kinase inhibitor, ROS1-positive NSCLC, taletrectinib, United States Food and Drug Administration

Nuvation Bio; FDA approval; Ibtrozi; taletrectinib; lung cancer; ROS1-positive NSCLC; oral treatment; tyrosine kinase inhibitor

Black Diamond Therapeutics Refocuses on Lung Cancer Drug BDTX-1535 Amid Workforce Reduction

10 months ago talkbio0Tagged BDTX-1535, Black Populations, Diamond Therapeutics, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Mutation, Protein-tyrosine kinase inhibitor, Tagrisso

Black Diamond Therapeutics, workforce reduction, lung cancer drug, BDTX-1535, EGFR mutations, Tagrisso, tyrosine kinase inhibitor